Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: frequency, characteristics and significance

• Published in: British journal of haematology 1999-01, Vol.104 (1), p.189-194
• Main Authors: Castellino, Sharon M., Combs, Martha R., Zimmerman, Sherri A., Issitt, Peter D., Ware, Russell E.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; alloantibodies; Anemia, Sickle Cell - blood; Anemia, Sickle Cell - immunology; Anemia, Sickle Cell - therapy; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Autoantibodies - analysis; Biological and medical sciences; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis; Child; children; Erythrocyte Transfusion - adverse effects; Erythrocytes - immunology; eythrocyte autoantibodies; Female; Hematology; Hemolysis; Humans; Immunoglobulin G - analysis; Isoantibodies - analysis; Male; Medical sciences; Sickle cell anemia; sickle cell disease; transfusion; Transfusions. Complications. Transfusion reactions. Cell and gene therapy; Treatment Outcome
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1046/j.1365-2141.1999.01127.x

The formation of erythrocyte autoantibodies following transfusion therapy has been described in case reports and small series. To determine the frequency, serological characteristics, and clinical significance of this phenomenon in paediatric patients with sickle cell disease, we analysed the patient database at the Duke University Pediatric Hematology Clinic. We identified children who received multiple erythrocyte transfusions, then reviewed clinical records to identify children who developed erythrocyte autoantibodies in association with transfusions. Among 184 paediatric patients who received multiple erythrocyte transfusions, 14 children (7.6%) developed warm (IgG) erythrocyte autoantibodies. Median transfusion exposure at the time of autoantibody formation was 24 erythrocyte units, range 3–341 units. The autoantibody reacted as a panagglutinin in 11 cases but had anti‐e specificity in three patients. Surface complement also was detected in five patients. Clinically significant haemolysis was documented in four patients, each of whom had both surface IgG and C3 detected. The development of erythrocyte autoantibodies was associated with the presence of erythrocyte alloantibodies. Formation of warm erythrocyte autoantibodies in association with transfusions is not rare in paediatric patients with sickle cell disease. Clinicians should be aware of this complication and recognize that the presence of surface C3 is often associated with significant haemolysis.